Co-Authors
This is a "connection" page, showing publications co-authored by DANIEL MUSHER and RICHARD HAMILL.
Connection Strength
1.191
-
Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother. 2007 Apr; 59(4):705-10.
Score: 0.295
-
Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005 Jun 01; 40(11):1586-90.
Score: 0.260
-
Adherence to clinical practice guidelines for the treatment of candidemia at a Veterans Affairs Medical Center. Int J Health Sci (Qassim). 2017 Jul-Sep; 11(3):18-23.
Score: 0.151
-
Cerebral Scedosporium apiospermum infection presenting with intestinal manifestations. Infection. 2013 Jun; 41(3):723-6.
Score: 0.112
-
Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006 Sep; 58(3):680-3.
Score: 0.071
-
Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis. 2006 Aug 15; 43(4):421-7.
Score: 0.071
-
Clostridium difficile lacks detectable superantigen activity. FEMS Immunol Med Microbiol. 2006 Jul; 47(2):275-7.
Score: 0.070
-
Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005 Sep; 5(9):549-57.
Score: 0.067
-
In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother. 2004 Oct; 48(10):4016-9.
Score: 0.062
-
Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol. 2006 Oct; 27(10):1051-6.
Score: 0.018
-
Spectrum of bacille Calmette-Gu?rin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis. 2003 Jan 15; 36(2):140-8.
Score: 0.014